RxDoctor Payments Data

Nikhita Dhruv, MD

Endocrinology, Diabetes & Metabolism · Melbourne, FLNPI 1710985593

Payments from drug & device makers

$143,062in general payments, 2019–2025

Across 829 payments — averaging $172.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$47K
  • Lilly USA, LLC$38K
  • AbbVie$18K
  • Medtronic$11K
  • Esperion Therapeutics, Inc.$10K
  • AstraZeneca$9K
  • plus $9K from 49 others

What the payments were for

  • Consulting fees$4,0003%
  • Speaking & faculty fees$100,06970%
  • Travel & lodging$22,40916%
  • Food & beverage$16,46312%
  • Education$560%
  • Gifts$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,062 in reported general payments places this provider in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$226,599
Medicare patients
384
Services billed
2,848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide464$707,617
MounjaroTirzepatide421$606,464
FarxigaDapagliflozin Propanediol444$479,704
TrulicityDulaglutide278$414,306
JardianceEmpagliflozin219$231,457
KerendiaFinerenone78$114,144
SynthroidLevothyroxine Sodium716$55,697
Repatha SureclickEvolocumab45$51,978
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro132$40,412
ProliaDenosumab24$39,314
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp103$31,185
NexletolBempedoic Acid29$30,307
VascepaIcosapent Ethyl33$29,463
FiaspInsulin Aspart (Niacinamide)24$26,227
EntrestoSacubitril/Valsartan20$22,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Humulin 70-30$38,100$1,044,452771 claims
Novo NordiskOzempic, Fiasp, Novolog, Novolog Mix 70-30$757$748,675520 claims
AstraZenecaFarxiga$9,253$479,704444 claims
Boehringer IngelheimJardiance$446$231,457219 claims
BayerKerendia$233$114,14478 claims
AbbVieSynthroid$17,846$55,697716 claims
AmgenProlia$47,457$39,31424 claims
Esperion Therapeutics, Inc.Nexletol$9,834$30,30729 claims
NovartisEntresto$153$22,87020 claims
MerckJanuvia$98$12,61613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →